FDA Determines Regulatory Review Period for PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN, a medical device, following the submission of applications to the U.S. Patent and Trademark Office (USPTO).